Timothy C. Stonesifer, an insider at Insulet Corp (PODD), has acquired 4,591 shares of the company at a price of $311.73 per share, resulting in a total transaction value of $1.43 million. This purchase, executed on December 4, 2025, brings Stonesifer's total holdings to 4,591 shares.
Insulet Corp, a medical device company based in Acton, Massachusetts, develops and markets insulin infusion systems for individuals with insulin-dependent diabetes. The company, which went public on May 15, 2007, has a market capitalisation of $23.3 billion and reported a trailing twelve months (TTM) price-to-earnings (P/E) ratio of 94.63 alongside an earnings per share (EPS) of 3.40.
The upcoming earnings report is scheduled for August 5, 2026, with analysts estimating an EPS of $1.47 and revenue of $789.7 million. The buy transaction by Stonesifer may reflect confidence in the company's future performance, though insider trading activity should be considered alongside broader market factors and not in isolation. Such decisions reflect the insights that insiders may have regarding their company's trajectory, providing transparency into executive sentiment.
Investors are encouraged to examine trends in insider transactions across multiple periods and individuals to gain a clearer perspective on potential market signals.